Literature DB >> 30833131

A systematic review of outcome in intramedullary ependymoma and astrocytoma.

Kirsty R Hamilton1, Sharon Si Lee2, James C Urquhart3, Benjamin P Jonker4.   

Abstract

The objective was to determine the impact of surgical resection and adjuvant therapies on survival in intramedullary ependymoma and astrocytoma. Secondary goals were to determine predictors of survival in surgical patients including histological grading, age and gender. Searching of Medline, Embase and Clinicaltrials.gov databases were performed. Multivariate analyses were performed for overall survival (OS) and progression-free survival (PFS) through Monte Carlo methods and Maximum Likelihood Estimation. 57 articles detail results for 3022 patients. Meta-analysis revealed the following factors to have a statistically significant effect on OS. Patients undergoing gross-total resection (GTR) are 5.37 times more likely to survive than patients with lesser volumes of tumor resected (HR for OS 1.68, p < 0.01). High-grade tumors were associated with a 14 times risk of death over low-grade tumors (HR for OS 2.64, p < 0.01). Radiation increased the risk of mortality in low-grade tumors (HR for OS 5.20, p < 0.01), but decreased mortality in high-grade lesions (HR for OS 2.46, p < 0.01). Adult patients were more likely to die from disease compared with pediatric patients by a factor of 1.6 (HR for OS 0.47, p < 0.01). In PFS, radiotherapy was associated with a reduced time to recurrence (HR for PFS 1.90, p < 0.01). There was a male predominance of 58%. Gender did not influence survival. 79% of patients demonstrated stable or improved functional neurological outcomes six months post-operatively. Our data indicates GTR improves OS in all tumor grades. Radiation improves OS only in the presence of high-grade histology. Advancing age and high-grade histology are negative prognostic indicators.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Astrocytoma; Ependymoma; Intramedullary tumor; Radiotherapy; Spine

Mesh:

Year:  2019        PMID: 30833131     DOI: 10.1016/j.jocn.2019.02.001

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  12 in total

1.  Predictors of survival and time to progression following operative management of intramedullary spinal cord astrocytomas.

Authors:  Andrew M Hersh; Albert Antar; Zach Pennington; Nafi Aygun; Jaimin Patel; Earl Goldsborough; Jose L Porras; Aladine A Elsamadicy; Daniel Lubelski; Jean-Paul Wolinsky; George I Jallo; Ziya L Gokaslan; Sheng-Fu Larry Lo; Daniel M Sciubba
Journal:  J Neurooncol       Date:  2022-05-11       Impact factor: 4.130

2.  Pathological Classification of the Intramedullary Spinal Cord Tumors According to 2021 World Health Organization Classification of Central Nervous System Tumors, a Single-Institute Experience.

Authors:  Sung-Hye Park; Jae Kyung Won; Chi Heon Kim; Ji Hoon Phi; Seung-Ki Kim; Seung Hong Choi; Chun Kee Chung
Journal:  Neurospine       Date:  2022-09-30

3.  Image-Guided Robotic Radiosurgery for the Management of Intramedullary Spinal Cord Metastases-A Multicenter Experience.

Authors:  Felix Ehret; Carolin Senger; Markus Kufeld; Christoph Fürweger; Melina Kord; Alfred Haidenberger; Paul Windisch; Daniel Rueß; David Kaul; Maximilian Ruge; Christian Schichor; Jörg-Christian Tonn; Alexander Muacevic
Journal:  Cancers (Basel)       Date:  2021-01-15       Impact factor: 6.639

4.  Canadian Pediatric Neuro-Oncology Standards of Practice.

Authors:  Julie Bennett; Craig Erker; Lucie Lafay-Cousin; Vijay Ramaswamy; Juliette Hukin; Magimairajan I Vanan; Sylvia Cheng; Hallie Coltin; Adriana Fonseca; Donna Johnston; Andrea Lo; Shayna Zelcer; Saima Alvi; Lynette Bowes; Josée Brossard; Janie Charlebois; David Eisenstat; Kathleen Felton; Adam Fleming; Nada Jabado; Valérie Larouche; Geneviève Legault; Chris Mpofu; Sébastien Perreault; Mariana Silva; Roona Sinha; Doug Strother; Derek S Tsang; Beverly Wilson; Bruce Crooks; Ute Bartels
Journal:  Front Oncol       Date:  2020-12-22       Impact factor: 6.244

5.  Magnetic resonance imaging indicators for neurological outcome after surgery in patients with intramedullary spinal ependymomas.

Authors:  Yongqiang Ma; Bofeng Bai; Xihai Zhao; Lixue Wang; Benqi Zhao; Yi Guo; Hongfang Yin; Xiaofei Zhang; Zhuozhao Zheng
Journal:  Medicine (Baltimore)       Date:  2022-01-28       Impact factor: 1.889

6.  Complete Versus Incomplete Surgical Resection in Intramedullary Ependymomas: A Systematic Review and Meta-analysis.

Authors:  Farhad Salari; Mehdi Golpayegani; Mohsen Sadeghi-Naini; Sara Hanaei; Farhad Shokraneh; Ayat Ahmadi; Hamid Reza Khayat-Kashani; Alexander R Vacarro; Vafa Rahimi-Movaghar
Journal:  Global Spine J       Date:  2020-08-12

Review 7.  Spinal intramedullary schwannomas-report of a case and extensive review of the literature.

Authors:  V M Swiatek; K-P Stein; H B Cukaz; A Rashidi; M Skalej; C Mawrin; I E Sandalcioglu; B Neyazi
Journal:  Neurosurg Rev       Date:  2020-09-15       Impact factor: 3.042

8.  Clinical, radiological and molecular characterization of intramedullary astrocytomas.

Authors:  Laetitia Lebrun; Barbara Meléndez; Oriane Blanchard; Nancy De Nève; Claude Van Campenhout; Julie Lelotte; Danielle Balériaux; Matteo Riva; Jacques Brotchi; Michaël Bruneau; Olivier De Witte; Christine Decaestecker; Nicky D'Haene; Isabelle Salmon
Journal:  Acta Neuropathol Commun       Date:  2020-08-08       Impact factor: 7.801

9.  Correlation of Intraoperative Neurophysiological Parameters and Outcomes in Patients with Intramedullary Tumors.

Authors:  Leonardo Gilmone Ruschel; Afonso Aragão; Matheus Fernandes de Oliveira; Jerônimo Buzetti Milano; Mauricio Coelho Neto; Ricardo Ramina
Journal:  Asian J Neurosurg       Date:  2021-05-28

10.  Analyses of DNA Methylation Profiling in the Diagnosis of Intramedullary Astrocytomas.

Authors:  Laetitia Lebrun; Martin Bizet; Barbara Melendez; Barbara Alexiou; Lara Absil; Claude Van Campenhout; Nicky D'Haene; Sandrine Rorive; François Fuks; Christine Decaestecker; Isabelle Salmon
Journal:  J Neuropathol Exp Neurol       Date:  2021-08-11       Impact factor: 3.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.